FDA Public Workshop on Clinical Trial Diversity

FDA is holding a two-day virtual public workshop to enhance clinical study diversity. This workshop is being held on November 29 and 30, 2023 10 a.m. – 2 p.m. ET

FDA is seeking input on increasing the enrollment of historically underrepresented populations in clinical studies and ways to encourage clinical study participation that reflect the prevalence of the disease or condition among demographic subgroups.

Representatives from drug sponsors, medical device sponsors, clinical research organizations, academia, patients, and other stakeholders will share their experiences and approaches for increasing enrollment and encouraging participation of historically underrepresented populations in clinical studies.

Additional information about the public workshop along with registration details will follow in advance of the workshop.

CENTER FOR DRUG EVALUATION AND RESEARCH

DIVISION of DRUG INFORMATION

Your source for the latest drug information. Know the moment it happens.

Save the Date Two-Day Virtual Public Workshop to Enhance Clinical Study Diversity November 29 and 30, 2023 10 a.m. – 2 p.m. ET

The U.S. Food and Drug Administration, in collaboration with the Clinical Trials Transformation Initiative (CTTI), is convening a public workshop to solicit input on increasing the enrollment of historically underrepresented populations in clinical studies and encouraging clinical study participation that reflects the prevalence of the disease or condition among demographic subgroups. The meeting fulfills a requirement under section 3603 of the Food and Drug Omnibus Reform Act of 2022 (FDORA).

Please save the date for this free, two-day, virtual public workshop:

Wednesday, November 29, and Thursday, November 30, 2023

10 a.m. – 2 p.m. ET (same time on both dates)

Representatives from drug sponsors, medical device sponsors, clinical research organizations, academia, patients, and other stakeholders will share their experiences and approaches for increasing enrollment and encouraging participation of historically underrepresented populations in clinical studies.

Additional information about the public workshop along with registration details will follow in advance of the workshop.

Increasing diversity of study participants in clinical trials and expanding the pool of participants is very important to provide useful information on safety and efficacy of products in diverse people.

An older man with white hair, wearing a blue shirt and dark blazer, stands in front of a blurred indoor background, smiling at the camera—a confident professional among Chicago lawyers known for expertise in intellectual property law.

[email protected]

Washington, D.C. 202.672.5430

Related Insights

View All Posts

October 22, 2026 Foley Career Perspectives

Foley’s 2026 Senior Counsel Leadership Development Program Impacts Professional Growth, Relationships, and Engagement

Leadership development is an ongoing process of learning, reflection, and practical application. That progression was at the heart of Foley’s 2026 Senior Counsel Leadership Development Program, which brought together 20 senior counsel for a months-long experience designed to strengthen their leadership capabilities and prepare them for long-term success within the firm.

October 21, 2026 Foley Viewpoints

The $2,500 Question: What Employers Need to Know About Contributing to Trump Accounts

Trump accounts are not just a matter for families; they also give employers a new tax-advantaged benefit to offer to employees. The OBBBA created “Trump accounts,” or tax-advantaged savings accounts for children, and a companion tax break that lets employers contribute up to $2,500 per employee each year to the accounts of employees and their dependents.

October 21, 2026 Foley Viewpoints

No More Counting Zeros: IRS Proposed Rules Make Dependent Care FSA Testing Easier and May Open the Door to the $7,500 Limit

For many companies, the end of the plan year brings an unwelcome headache: the DCAP fails its nondiscrimination testing, and HCEs learn that their elections must be capped or that part of their benefit will be taxable. Newly proposed regulations provide some relief for these issues.

Popular Searches

FDA Public Workshop on Clinical Trial Diversity

Author(s)

David L. Rosen

Related Insights

Foley’s 2026 Senior Counsel Leadership Development Program Impacts Professional Growth, Relationships, and Engagement

The $2,500 Question: What Employers Need to Know About Contributing to Trump Accounts

No More Counting Zeros: IRS Proposed Rules Make Dependent Care FSA Testing Easier and May Open the Door to the $7,500 Limit